COMMUNIQUÉS West-GlobeNewswire
-
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
08/10/2018 - 07:16 -
Health Needs Spike for Survivors of Indonesia’s Earthquake and Tsunami
06/10/2018 - 18:31 -
Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer from LIBRETTO-001 at the 88th Annual Meeting of the American Thyroid Association
06/10/2018 - 15:05 -
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
06/10/2018 - 13:30 -
Akcea et Ionis annoncent l’homologation de TEGSEDIMC (inotersen pour injection) au Canada
06/10/2018 - 10:31 -
Adamas Announces New Employment Inducement Grant
05/10/2018 - 23:51 -
Akcea Announces Its Access and Distribution Strategy for TEGSEDI™ (inotersen)
05/10/2018 - 23:33 -
Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
05/10/2018 - 23:32 -
Cogentix Medical, Inc. / Laborie Medical Technologies Canada ULC Merger Litigation
05/10/2018 - 23:00 -
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/10/2018 - 22:30 -
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/10/2018 - 22:05 -
Solid Biosciences to Present at the Chardan Genetic Medicines Conference
05/10/2018 - 22:05 -
Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018
05/10/2018 - 22:01 -
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/10/2018 - 22:00 -
Genetic Testing: Thinking About An At-Home Test for Alzheimer’s Risk Gene?
05/10/2018 - 21:24 -
Sienna Announces Third Quarter 2018 Results Release Date and Conference Call
05/10/2018 - 19:37 -
GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs, Raising Gross Proceeds of $345 Million and Full Exercise of Underwriters' Option to Purchase Additional ADSs
05/10/2018 - 16:34 -
Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences
05/10/2018 - 16:01 -
About acquisition of significant shareholding
05/10/2018 - 15:42
Pages